Search | Clinical Trials Finder

Conditions: Exposure to Man-made Visible Light
Interventions: 670 nm light, octafluropropane; Device · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 59 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hematologic Malignancies
Interventions: extracorporeal photopheresis, Pentostatin, Total Body Irradiation; Procedure · Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas

Conditions: Head and Neck Cancer
Interventions: Bevacizumab, Erlotinib, Paclitaxel, 5-FU, Radiation Therapy; Drug · Radiation
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 7
States / cities: Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more

Conditions: Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions: Low intensity anticoagulation, Moderate Intensity Anticoagulation; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Down Syndrome, Regression
Interventions: Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 30 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Aurora, Colorado

Conditions: Breast Cancer
Interventions: Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions: BPX-601, Rimiducid; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Cancer of the Cervix
Interventions: Granisetron, Ondansetron, Questionnaires, Study Drug Diary; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Type1 Diabetes Mellitus
Interventions: Aspart; Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Myelofibroses
Interventions: Pevonedistat, Ruxolitinib, Peripheral blood draw, Skin biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes
Interventions: Guardian® blood-sugar monitoring device; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 6
States / cities: Dallas, Texas • Galveston, Texas • Houston, Texas + 2 more

Conditions: Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS); Drug · Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Cancer, Neoplasms, Tumors
Interventions: OSI-906 and Pemetrexed; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Post-operative Pain, Respiratory Depression
Interventions: Dexmedetomidine, Placebo (Normal Saline); Drug · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Secondary Hyperparathyroidism
Interventions: Teriparatide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years to 59 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain, Shoulder Injury
Interventions: Preemptive Interscalene Block - Single Shot, Postoperative Interscalene Block- Single Shot, Preemptive Interscalene Block - Catheter, Postoperative Interscalene Block - Catheter; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 21 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions: Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Advanced Non-Hematologic Malignancies
Interventions: PF-04605412; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
Interventions: TBio-4101, Pembrolizumab, Platinum based chemotherapy, Cyclophosphamide, Fludarabine, Aldesleukin; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Pancreatic Cancer
Interventions: Nab paclitaxel, Gemcitabine, Dociparstat; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 16
States / cities: Scottsdale, Arizona • Burbank, California • Greenbrae, California + 12 more

Conditions: Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions: Regadenoson; Optison; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 30 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: PreDiabetes
Interventions: Intralipid and heparin, Saline; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Peripheral Blood Flow Responses to Electromagnetic Energy

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

Strategies for Anticoagulation During Venovenous ECMO

Therapies for Down Syndrome Regression Disorder

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Continuous Glucose Monitoring in Critically Ill

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

Angiotensin 2 for AKI After OLT

Efficacy of Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Intervention

Allo HSCT Using RIC for Hematological Diseases

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Regadenoson Real Time Perfusion Imaging Trial-Optison

Insulin and Insulin Pulses During Fasting